Details

Antibiotic Drug Resistance


Antibiotic Drug Resistance


1. Aufl.

von: José-Luis Capelo-Martínez, Gilberto Igrejas

226,99 €

Verlag: Wiley
Format: PDF
Veröffentl.: 09.09.2019
ISBN/EAN: 9781119282532
Sprache: englisch
Anzahl Seiten: 720

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

This book presents a thorough and authoritative overview of the multifaceted field of antibiotic science – offering guidance to translate research into tools for prevention, diagnosis, and treatment of infectious diseases.  Provides readers with knowledge about the broad field of drug resistance Offers guidance to translate research into tools for prevention, diagnosis, and treatment of infectious diseases Links strategies to analyze microbes to the development of new drugs, socioeconomic impacts to therapeutic strategies, and public policies to antibiotic-resistance-prevention strategies
List of Contributors xix Preface xxv About the Editors xxvii Part I Current Antibiotics and Their Mechanism of Action 1 1 Resistance to Aminoglycosides: Glycomics and the Link to the Human Gut Microbiome 3Viviana G. Correia, Benedita A. Pinheiro, Ana Luísa Carvalho, and Angelina S. Palma 1.1 Aminoglycosides as Antimicrobial Drugs 3 1.1.1 The Structure of Aminoglycosides 5 1.1.2 Mechanisms of Action 8 1.2 Mechanisms of Resistance 10 1.2.1 Aminoglycoside?Modifying Enzymes 10 1.2.2 Mutation or Modification of Ribosomal Target Sequences 13 1.2.3 Changes in Uptake and Efflux 14 1.3 Development of New AGAs: The Potential of Glycomics 16 1.3.1 Exploitation of Carbohydrate Chemistry to Study Structure–Activity Relationship of Aminoglycoside Derivatives 17 1.3.2 Aminoglycoside Microarrays to Screen Interactions of Antibiotics with RNAs and Proteins 18 1.4 Influence of the Human Microbiome in Aminoglycoside Resistance 20 1.4.1 The Effect of Antibiotic?Induced Alterations 21 1.4.2 A Reservoir of Antibiotic Resistance 24 1.4.3 Strategies to Modulate the Human Microbiome 25 1.5 Conclusions and Outlook 26 Acknowledgments 27 References 28 2 Mechanisms of Action and of Resistance to Quinolones 39José L. Martínez 2.1 Introduction 39 2.2 Mechanism of Action of Quinolones 40 2.3 Mutations in the Genes Encoding the Targets of Quinolones 41 2.4 Multidrug Efflux Pumps and Quinolone Resistance 42 2.5 Transferable Quinolone Resistance 43 2.6 Stenotrophomonas maltophilia and Its Uncommon Mechanisms of Resistance to Quinolones 46 Acknowledgments 47 References 47 3 Beta?Lactams 57Luz Balsalobre, Ana Blanco, and Teresa Alarcón 3.1 Introduction 57 3.2 Chemical Structure 58 3.3 Classification and Spectrum of Activity 59 3.3.1 Penicillins 59 3.3.2 Cephalosporins 61 3.3.3 Monobactams 63 3.3.4 Carbapenems 64 3.3.5 Beta?Lactam Associated with Beta?Lactamase Inhibitors 64 3.4 Mechanism of Action 66 3.5 Activity of Beta?Lactams Against Multiresistant Bacteria 68 3.6 Conclusions 70 References 70 4 Glycopeptide Antibiotics: Mechanism of Action and Recent Developments 73Paramita Sarkar and Jayanta Haldar 4.1 Introduction 73 4.2 Naturally Occurring Glycopeptide Antibiotics 75 4.3 Mechanism of Action of Glycopeptide Antibiotics 76 4.4 Resistance to Glycopeptides 78 4.5 Second?Generation Glycopeptides 79 4.5.1 Telavancin 79 4.5.2 Dalbavancin 80 4.5.3 Oritavancin 80 4.6 Strategies to Overcome Resistance to Glycopeptides 81 4.6.1 Modifications That Enhance the Binding Affinity to Target Pentapeptide 81 4.6.2 Incorporation of Lipophilicity 85 4.6.3 Incorporation of Lipophilic Cationic Moieties to Impart Membrane Disruption Properties 86 4.6.4 Incorporation of Metal Chelating Moiety to Vancomycin to Impart New Mechanism of Action 88 4.7 Glycopeptides Under Clinical Trials 88 4.8 Glycopeptide Antibiotics: The Challenges 90 References 91 5 Current Macrolide Antibiotics and Their Mechanisms of Action 97S. Lohsen and D.S. Stephens 5.1 Introduction 97 5.2 Structure of Macrolides 99 5.3 Macrolide Mechanisms of Action 101 5.4 Clinical Use of Macrolides 104 5.5 Next?Generation Macrolides and Future Use 107 References 109 Part II Mechanism of Antibiotic Resistance 119 6 Impact of Key and Secondary Drug Resistance Mutations on Structure and Activity of ??Lactamases 121Egorov Alexey, Ulyashova Mariya, and Rubtsova Maya 6.1 Introduction 121 6.2 Structure of the Protein Globule of TEM?Type ??Lactamases: Catalytic and Mutated Residues 122 6.2.1 Catalytic Site of ??Lactamase TEM?1 124 6.2.2 Mutations Causing Phenotypes of TEM?Type ??Lactamases 125 6.3 Effect of the Key Mutations on Activity of TEM?Type ??Lactamases 127 6.3.1 Single Key Mutations in TEM?Type ESBLs (2be) 128 6.3.2 Combinations of Key Mutations in TEM?Type ESBLs (2be) 130 6.3.3 Key Mutations in IRT TEM?Type ??Lactamases (2br) 131 6.3.4 Single Key Mutations in IRT TEM?Type ??Lactamases (2br) 131 6.3.5 Combinations of Key Mutations in IRT TEM?Type ??Lactamases (2br) 133 6.3.6 Combinations of Key ESBL and IRT Mutations in CMT TEM?Type ??Lactamases (2ber) 133 6.4 Effect of Secondary Mutations on the Stability of TEM?Type ??Lactamases 134 6.5 Conclusions 135 Abbreviations 136 References 137 7 Acquired Resistance from Gene Transfer 141Elisabeth Grohmann, Verena Kohler, and Ankita Vaishampayan 7.1 Introduction 141 7.2 Horizonal Gene Transfer: A Brief Overview 143 7.2.1 Transformation 144 7.2.2 Transduction 144 7.2.3 Conjugation 145 7.3 Conjugative Transfer Mechanisms 145 7.3.1 Conjugative Transfer of Plasmids 146 7.3.2 Conjugative Transfer of Integrative Conjugative Elements 148 7.3.3 Conjugative Transfer of Other Integrative Elements 150 7.4 Antibiotic Resistances and Their Transfer 151 7.4.1 Dissemination of Carbapenem Resistance Among Bacterial Pathogens 151 7.4.2 Dissemination of Cephalosporin Resistance Among Bacterial Pathogens 153 7.4.3 Dissemination of Methicillin Resistance Among Bacterial Pathogens 153 7.4.4 Dissemination of Vancomycin Resistance Among Bacterial Pathogens 154 7.4.5 Dissemination of Fluoroquinolone Resistance Among Bacterial Pathogens 154 7.4.6 Dissemination of Penicillin and Ampicillin Resistance Among Bacterial Pathogens 155 7.5 Nanotubes Involved in Acquisition of Antibiotic Resistances 155 7.6 Conclusions and Outlook 156 Abbreviations 156 References 157 8 Antimicrobial Efflux Pumps 167Manuel F. Varela 8.1 Bacterial Antimicrobial Efflux Pumps 167 8.1.1 Active Drug Efflux Systems 167 8.1.2 Secondary Active Drug Transporters 169 References 173 9 Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved 181Anne Jolivet?Gougeon and Martine Bonnaure?Mallet 9.1 Introduction 181 9.2 Reasons for Failure of Antibiotics in Biofilms 182 9.2.1 Failure of Antibiotics to Penetrate Biofilm: Active Antibiotics on the Biofilm 182 9.2.2 Outer Membrane Vesicles (OMVs) 183 9.2.3 Horizontal Transfer of Encoding ??Lactamase Genes 184 9.2.4 Influence of Subinhibitory Concentrations of Antibiotics on Biofilm 184 9.2.5 Small Colony Variants (SCVs), Persistence (Persisters), and Toxin–Antitoxin (TA) Systems 186 9.2.6 Quorum Sensing: Bacterial Metabolites 191 9.2.7 Extracellular DNA 191 9.2.8 Nutrient Limitation 192 9.2.9 SOS Inducers (Antibiotics and Others) 192 9.2.10 Hypermutator Phenotype 192 9.2.11 Multidrug Efflux Pumps 193 9.3 Usual and Innovative Means to Overcome Biofilm Resistance in Biofilms 193 9.3.1 Antibiotics (Bacteriocins) Natural and Synthetic Molecules: Phages 194 9.3.2 Efflux Pump Inhibitors 195 9.3.3 Anti?Persisters: Quorum?Sensing Inhibitors 195 9.3.4 Enzymes 196 9.3.5 Electrical Methods 196 9.3.6 Photodynamic Therapy 196 9.4 Conclusion 197 Acknowledgments 197 Conflict of Interest 197 References 197 Part III Socio-Economical Perspectives and Impact of AR 211 10 Sources of Antibiotic Resistance: Zoonotic, Human, Environment 213Ivone Vaz?Moreira, Catarina Ferreira, Olga C. Nunes, and Célia M. Manaia 10.1 The Antibiotic Era 213 10.2 Intrinsic and Acquired Antibiotic Resistance 214 10.3 The Natural Antibiotic Resistome 215 10.4 The Contaminant Resistome 215 10.5 Evolution of Antibiotics Usage 216 10.6 Antibiotic Resistance Evolution 219 10.7 Stressors for Antibiotic Resistance 219 10.8 Paths of Antibiotic Resistance Dissemination 221 10.9 Antibiotic Resistance in Humans and Animals 224 10.10 Final Considerations 227 References 228 11 Antibiotic Resistance: Immunity?Acquired Resistance: Evolution of Antimicrobial Resistance Among Extended?Spectrum ??Lactamases and Carbapenemases in Klebsiella pneumonia and Escherichia coli 239Isabel Carvalho, Nuno Silva, João Carrola, Vanessa Silva, Carol Currie, Gilberto Igrejas, and Patrícia Poeta 11.1 Overview of Antibiotic Resistance as a Worldwide Health Problem 239 11.2 Objectives 241 11.3 Causes of Antimicrobial Resistance 242 11.4 Enterobacteriaceae: General Characterization 243 11.4.1 Escherichia coli 243 11.4.2 Klebsiella pneumoniae 244 11.5 Current Antibiotic Resistance Threats 245 11.5.1 Carbapenem?Resistant Enterobacteriaceae 245 11.5.2 Extended?Spectrum ??Lactamase 247 11.6 Consequences and Future Strategies to Brace the Antibiotic Backbone 250 11.7 Concluding Remarks and Future Perspectives 251 Acknowledgments 252 References 252 12 Extended?Spectrum???Lactamase and Carbapenemase?Producing Enterobacteriaceae in Food?Producing Animals in Europe: An Impact on Public Health? 261Nuno Silva, Isabel Carvalho, Carol Currie, Margarida Sousa, Gilberto Igrejas, and Patrícia Poeta 12.1 Extended?Spectrum ??Lactamase 261 12.1.1 ESBL?Producing Enterobacteriaceae in Food Animals 262 12.2 Carbapenemases 265 12.3 Concluding Remarks 267 References 268 Part IV Therapeutic Strategy for Overcoming AR 275 13 AR Mechanism?Based Drug Design 277Mire Zloh 13.1 Introduction 277 13.2 Drug Design Principles 279 13.3 Identification of Novel Targets and Novel Mechanisms of Action 282 13.4 Efflux Pump Inhibitors 286 13.5 Design of Inhibitors of Drug?Modifying Enzymes 294 13.6 Antimicrobial Peptides 297 13.7 Other Approaches to Overcome Bacterial Resistance 299 13.8 Conclusion 300 References 300 14 Antibiotics from Natural Sources 311David J. Newman 14.1 Introduction 311 14.1.1 The Origin of Microbial Resistance Gene Products 311 14.2 Organization of the Following Sections 312 14.3 Peptidic Antibiotics (Both Cyclic and Acyclic) 312 14.3.1 Tyrocidines, Gramacidins, and Derivatives 312 14.3.2 Streptogramins and Derivatives: Cyclic Peptides 313 14.3.3 Arylomycins (Lipopeptide and Modification, Preclinical) 313 14.3.4 Daptomycin (Cyclic Depsilipopeptide) 314 14.3.5 Colistins (Cyclic Peptides with a Lipid Tail) 315 14.3.6 Glycopeptides 317 14.3.7 Host Defense Peptides 319 14.4 ??Lactams: Development, Activities, and Chemistry 321 14.4.1 Combinations with ??Lactamase Inhibitors 322 14.5 Aminoglycosides 323 14.5.1 Streptomycin 323 14.5.2 Plazomicin 323 14.6 Early Tetracyclines: Aureomycin and Terramycin 324 14.6.1 Semisynthetic Tetracyclines from 2005 324 14.7 Erythromycin Macrolides 326 14.7.1 Recent Semisynthetic Macrolides 326 14.8 Current Methods of “Discovering Novel Antibiotics” 328 14.8.1 Introduction 328 14.8.2 Initial Rate?Limiting Step (Irrespective of Methods) 328 14.8.3 Genomic Analyses of Whole Microbes 329 14.8.4 Isolated Genomics 329 14.8.5 New Sources (and Old Ones?) for Investigation 331 14.8.6 “Baiting” for Microbes 331 14.8.7 Use of Elicitors 333 14.9 Conclusions 333 14.9.1 Funding? 334 14.9.2 The “Take?Home Lesson” 334 References 334 15 Bacteriophage Proteins as Antimicrobials to Combat Antibiotic Resistance 343Hugo Oliveira, Luís D. R. Melo, and Sílvio B. Santos 15.1 Introduction 343 15.2 Polysaccharide Depolymerases 346 15.2.1 Depolymerase Structure 348 15.2.2 Depolymerase Classification 349 15.2.3 Depolymerase Activity Assessment 350 15.2.4 Depolymerases as Antimicrobials 351 15.2.5 Remarks on Depolymerases 355 15.3 Peptidoglycan?Degrading Enzymes 356 15.3.1 Virion?Associated Lysins (VALs) 358 15.3.2 Gram?Positive Targeting Endolysins 365 15.3.3 Gram?Negative Targeting Endolysins 374 15.4 Holins 388 15.4.1 Holin Structure 388 15.4.2 Holins as Antimicrobials 389 15.4.3 Remarks on Holins 390 15.5 Final Considerations 390 References 392 16 Antibiotic Modification Addressing Resistance 407Haotian Bai and Shu Wang 16.1 Chemical Synthesis of New Antibiotics 407 16.2 Antibiotic Modification with Targeted Groups 413 16.3 Antibiotic Modification with Photo?Switching Units 417 16.4 Antibiotic Modification by Supramolecular Chemistry 420 16.5 Antibiotic Modification by Complexed with Other Materials 423 16.6 Conclusion 425 References 425 17 Sensitizing Agents to Restore Antibiotic Resistance 429Anton Gadelii, Karl?Omar Hassan, and Anders P. Hakansson 17.1 Introduction 429 17.2 Sensitizing Strategies Directly Targeting Resistance Mechanisms 430 17.2.1 Inhibition of ??Lactamases 430 17.2.2 Drug Efflux Pump Inhibitors (EPIs) 433 17.3 Sensitizing Strategies Circumventing Resistance Mechanisms 435 17.3.1 Manipulating Bacterial Homeostasis 435 17.3.2 Cell Wall/Membrane Proteins 437 17.3.3 Biofilms and Quorum Sensing 438 17.3.4 Persister Cells 440 17.3.5 Targeting Nonessential Genes/Proteins 441 17.3.6 Bacteriophages 441 17.4 Using and Strengthening the Human Immune System Against Resistant Bacteria 441 17.4.1 Strengthening Host Immune System Function 441 17.4.2 Antimicrobial Peptides (AMPs) 443 17.5 Conclusion 443 References 444 18 Repurposing Antibiotics to Treat Resistant Gram?Negative Pathogens 453Frank Schweizer 18.1 Introduction 453 18.2 Anti?Virulence Strategy 454 18.3 Antibiotic Combination Strategy 454 18.4 Antibiotic–Antibiotic Combination Approach 455 18.5 Antibiotic–Adjuvant Combination Approach 456 18.6 ??Lactam and ??Lactamase Inhibitor Combination 456 18.7 Imipenem–Cilastatin/Relebactam Triple Combination 457 18.8 Aspergillomarasmine A 458 18.9 Intrinsic Resistance Challenges and Strategies to Overcome Them 458 18.10 Repurposing of Hydrophobic Antibiotics with High Molecular Weight by Enhancing Outer Membrane Permeability Using Polybasic Adjuvants 461 18.11 Repurposing of Hydrophobic Antibiotics with Large Molecular Weight and Other Antibacterials as Antipseudomonal Agents Using Polybasic Adjuvants 464 18.12 Repurposing of Antibiotics as Potent Agents Against MDR GNB 467 18.13 Outlook and Conclusions 468 References 468 19 Nontraditional Medicines for Treatment of Antibiotic Resistance 477Ana Paula Guedes Frazzon, Michele Bertoni Mann, and Jeverson Frazzon 19.1 Introduction 477 19.2 Antibodies 478 19.2.1 Raxibacumab Versus Bacillus anthracis 478 19.2.2 Bezlotoxumab Versus Clostridium difficile 479 19.2.3 Panobacumab Versus Pseudomonas aeruginosa 479 19.2.4 LC10 Versus Staphylococcus aureus 480 19.3 Immunomodulators 481 19.3.1 Antibodies plus Polymyxins 481 19.3.2 Antibodies plus Vitamin D 482 19.3.3 Antibodies plus Clavanin 482 19.3.4 Antibodies plus Reltecimod 483 19.4 Potentiators of Antibiotic Activity 483 19.4.1 Antibiotic–Antibiotic Combinations 484 19.4.2 Pairing of Antibiotic with Nonantibiotic 485 19.5 Bacteriophages 488 19.5.1 Life Cycles of Bacteriophages 488 19.5.2 Bacteriophage Therapy 489 19.5.3 Phage Enzymes 490 19.5.4 Concerns About the Application of Phage to Treat Bacteria 491 19.6 Therapy with Essential Oils 491 19.7 Microbiota?Based Therapy 495 19.7.1 Microbiota Modulation 495 19.7.1.1 Probiotics 496 19.7.1.2 Prebiotics 496 19.7.2 Stool Microbiota Transplant 496 Further Reading 497 20 Therapeutic Options for Treatment of Infections by Pathogenic Biofilms 503Bruna de Oliveira Costa, Osmar Nascimento Silva, and Octávio Luiz Franco 20.1 Introduction 503 20.2 Antibiotic Therapy for the Treatment of Pathogenic Biofilms 504 20.2.1 Monotherapy 504 20.2.2 Antibiotic Combination Therapy 505 20.3 New Findings for the Treatment of Pathogenic Biofilms 507 20.3.1 AMPs Applied to Treatment Pathogenic Biofilms 507 20.3.2 Bacteriophage Therapy Anti?Biofilm 514 20.3.3 Nanotechnology Applied to the Treatment of Pathogenic Biofilms 517 20.4 Conclusion and Future Directions 519 References 520 Part V Strategies to Prevent the Spread of AR 533 21 Rapid Analytical Methods to Identify Antibiotic?Resistant Bacteria 535John B. Sutherland, Fatemeh Rafii, Jackson O. Lay, Jr., and Anna J. Williams 21.1 Introduction 535 21.2 Standard Methods for Antibiotic Sensitivity Testing 536 21.3 Rapid Cultural Methods 537 21.4 Rapid Serological Methods 540 21.5 Rapid Molecular (Genetic) Methods 540 21.6 Mass Spectrometric Methods 545 21.7 Flow Cytometric Methods 549 21.8 Conclusions 550 Acknowledgments 553 References 553 22 Effective Methods for Disinfection and Sterilization 567Lucía Fernández, Diana Gutiérrez, Beatriz Martínez, Ana Rodríguez, and Pilar García 22.1 Introduction 567 22.2 Disinfection and Sterilization: Methods and Factors Involved in Their Efficacy 569 22.2.1 Methods of Sterilization and Disinfection 570 22.2.2 Factors Influencing Disinfection and Sterilization Efficacy 570 22.3 Resistance to Disinfectants 571 22.3.1 Molecular Mechanisms of Biocide Resistance 571 22.3.2 Biofilms 572 22.3.3 Cross?Resistance Between Antibiotics and Disinfectants 574 22.4 New Technologies as Alternatives to Classical Disinfectants 575 22.4.1 Chemical and Physical Disinfectants 575 22.4.2 Antimicrobial Surfaces 578 22.4.3 Biological Disinfectants 578 22.5 Current Legislation 579 22.6 Conclusions 581 References 582 23 Strategies to Prevent the Spread of Antibiotic Resistance: Understanding the Role of Antibiotics in Nature and Their Rational Use 589Rustam Aminov 23.1 Introduction 589 23.2 Agriculture as the Largest Consumer of Antimicrobials 590 23.3 Antimicrobials and Antimicrobial Resistance 591 23.4 First?Generation Tetracyclines: Discovery and Usage 592 23.5 Tetracycline Resistance Mechanisms 593 23.6 Phylogeny of Tetracycline Resistance Genes 593 23.7 Second?Generation Tetracyclines 595 23.8 Third?Generation Tetracyclines 595 23.9 Resistance to Third?Generation Tetracyclines 596 23.10 Other Potential Resistance Mechanisms Toward Third?Generation Tetracyclines 597 23.11 Evolutionary Aspect of tet(X) 598 23.12 Ecological Aspects of tet(X) 599 23.13 Antibiotics and Antibiotic Resistance as Integral Parts of Microbial Diversity 602 23.14 The Role of Antibiotics in Natural Ecosystems 604 23.15 Low?Dose Antibiotics: Phenotypic Effects 605 23.16 Low?Dose Antibiotics: Genetic Effects 606 23.17 Regulation of Antibiotic Synthesis in Antibiotic Producers 608 23.18 Convergent Evolution of Antibiotics as Signaling Molecules 610 23.19 Carbapenems: Convergent Evolution and Regulation in Different Bacteria 611 23.20 Antibiotics and Antibiotic Resistance: Environmental and Anthropogenic Contexts 614 23.21 Conclusions 615 Conflict of Interest 616 References 616 Part VI Public Policy 637 24 Strategies to Reduce or Eliminate Resistant Pathogens in the Environment 639Johan Bengtsson?Palme and Stefanie Heß 24.1 Introduction 639 24.2 Sources of Resistant Bacteria in the Environment 640 24.3 Sewage and Wastewater 641 24.3.1 Sewage Treatment Plants 641 24.3.2 Non?Treated Sewage 643 24.3.3 Industrial Wastewater Effluents 643 24.3.4 Environmental Antibiotic Resistance is a Poverty Problem 644 24.4 Agriculture 646 24.4.1 Intensive, Large?Scale Animal Husbandry 646 24.4.2 Manure Application 647 24.4.3 Agriculture in Developing Countries 647 24.4.4 Aquaculture 648 24.5 De Novo Resistance Selection 649 24.6 Relevant Risk Scenarios 649 24.7 Management Options 653 24.7.1 Possible Interventions on the Level of Releases of Resistant Bacteria 653 24.7.2 Restricting Transmission of Resistant Bacteria from the Environment 657 24.7.3 Better Agriculture Practices to Sustain the Lifespans of Antibiotics 658 24.7.4 Limiting Selection for Resistance in the Environment 659 24.8 Final Remarks 661 Acknowledgments 662 Conflict of Interest 662 References 662 Index 675
JOSÉ-LUIS CAPELO-MARTÍNEZ PHD, is Associate Professor in the Department of Chemistry of the Faculty of Science and Technology of the NOVA University of Lisbon. GILBERTO IGREJAS PHD, is an Associate Professor with habilitation in the Department of Genetics and Biotechnology at the University of Trás-os-Montes and Alto Douro in Portugal.
A COMPREHENSIVE REVIEW OF THE MULTIFACETED FIELD OF ANTIBIOTIC SCIENCE In recent years bacterial resistance to antibiotics has reached new and disturbing heights. Antibiotic Drug Resistance offers a comprehensive overview of the complex field of antibiotic science. The authors—noted experts in the field—present an authoritative guide that translates current research into tools for prevention, diagnosis, and treatment of infectious diseases. Antibiotic Drug Resistance explores the significant challenge of resistance to antibiotic drugs and examines a wide range of topics. The book addresses the mechanisms of action of the antibiotics used today such as aminoglycosides, quinolones, betalactams, glycopeptides, and macrolides. The authors explore the strategies devoted to overcoming antibiotic resistance and include information on new techniques for designing drugs, antibiotics from natural sources, approaches based on antimicrobials and bacteriophages, and more. This important book: Provides the essential knowledge about the broad field of drug resistance Offers information on the tools for prevention, diagnosis, and treatment of infectious diseases Links strategies to analyze microbes to the development of new drugs Offers data on sensitizing agents to restore antibiotic activity, non-traditional medicines, and therapeutic options to treat infections caused by pathogenic bilfilms Written for pharmaceutical and medicinal chemists, microbiologists, biochemists, and others, Antibiotic Drug Resistance offers information on the current antibiotics and their mechanism of action and mechanism of antibiotic resistance. It also provides material on a socio-economic perspective, therapeutic approaches, prevention strategies, and public policy.

Diese Produkte könnten Sie auch interessieren:

Hot-Melt Extrusion
Hot-Melt Extrusion
von: Dennis Douroumis
PDF ebook
126,99 €
Hot-Melt Extrusion
Hot-Melt Extrusion
von: Dennis Douroumis
EPUB ebook
126,99 €
Surface Science
Surface Science
von: Kurt W. Kolasinski
EPUB ebook
56,99 €